Most previous patient-reported outcome results for CAR T-cell therapy have come from clinical trials testing these treatments, but information on how patients experience this treatment in real-world settings is scarce.
Dr Fabio Efficace and Dr Alice Di Rocco discuss their recent prospective study to measure real-world patient-reported symtomatic adverse events in those receiving CAR T-cell therapy for aggressive B-cell lymphomas, and how these outcomes match those reported by the physicans treating the patients. They discuss some of the rich and varied findings that they uncovered from their study.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Lancet Group. Innehållet i podden är skapat av The Lancet Group och inte av,
eller tillsammans med, Poddtoppen.
